false
Catalog
SHM's Clinical Quick Talks
Updates in Steatotic Liver Disease: MASLD and MASH
Updates in Steatotic Liver Disease: MASLD and MASH
Back to course
Pdf Summary
The document discusses updates in steatotic liver disease, highlighting the changes in nomenclature with the introduction of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). MASLD replaces NAFLD to better describe a condition driven by cardiometabolic risk factors, with MASLD progressing to MASH and eventually cirrhosis if untreated. Diagnosis of MASLD involves hepatic steatosis and cardiometabolic factors, while MASH includes evidence of hepatocellular injury, fibrosis, and inflammation. Treatment focuses on lifestyle modifications, diet, and exercise, with limited targeted therapies available for MASH. Complications of steatotic liver disease include an increased risk of diabetes, CKD, cirrhosis, and hepatocellular carcinoma. The document also covers the clinical stages of MASH, methods of diagnosis such as liver biopsy and non-invasive imaging techniques, and highlights key clinical pearls regarding cirrhosis, lean MAFLD, and dietary considerations in hepatic encephalopathy management. Lastly, it emphasizes the importance of early detection and intervention in managing steatotic liver disease to prevent disease progression and associated complications.
Asset Subtitle
Kimberly Tena Diaz, Alexander Garcia, Avneet Singh, Jonah Landau, Sabrina Gordon
Keywords
Steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease
MASLD
Metabolic dysfunction-associated steatohepatitis
MASH
NAFLD
Hepatic steatosis
Cardiometabolic factors
Cirrhosis
Hepatocellular carcinoma
×
Please select your language
1
English